The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
| Autor: | David Simpson, Andrew Grigg, Kerry Taylor, Constantine S. Tam, Anne-Marie Watson, Jason Butler, Anthony K. Mills, David Joske, Susan Branford, Kate Burbury, Henry Januszewicz, Robin Filshie, Abbey Willcox, Masa Lasica, Max Wolf, David M. Ross |
|---|---|
| Přispěvatelé: | Lasica, Masa, Willcox, Abbey, Burbury, Kate, Ross, David M, Branford, Susan, Butler, Jason, Filshie, Robin, Januszewicz, Henry, Joske, David, Mills, Anthony, Simpson, David, Tam, Constantine, Taylor, Kerry, Watson, Anne Marie, Wolf, Max, Grigg, Andrew |
| Rok vydání: | 2019 |
| Předmět: |
Oncology
Adult Cancer Research medicine.medical_specialty nil otinib medicine.drug_class Antiviral Agents Tyrosine-kinase inhibitor Cohort Studies 03 medical and health sciences Young Adult tyrosine kinase inhibitor 0302 clinical medicine Pharmacotherapy chronic myeloid leukemia Pregnancy Internal medicine Leukemia Myelogenous Chronic BCR-ABL Positive medicine Humans Protein Kinase Inhibitors business.industry Pregnancy Outcome Imatinib Hematology medicine.disease respiratory tract diseases Dasatinib Clinical research Treatment Outcome imatinib Nilotinib 030220 oncology & carcinogenesis Case-Control Studies Drug Therapy Combination Female pregnancy Interferons business 030215 immunology medicine.drug Chronic myelogenous leukemia Follow-Up Studies |
| Zdroj: | Leukemialymphoma. 60(7) |
| ISSN: | 1029-2403 |
| Popis: | The management of CML in pregnancy is challenging with the need to balance disease control against potential teratogenic effects of TKI therapy. In this multi-center case-cohort study of 16 women in chronic phase, CML ceased TKI treatment pre- or post-conception during their first pregnancy. Thirteen patients were on imatinib; 9 ceased their TKI prior to conception and 7 ceased at pregnancy confirmation. Twelve patients had achieved either MMR or better at time of TKI cessation. Eleven women lost MMR during pregnancy and two patients lost CHR. Fourteen women reestablished MMR on TKI recommenced. The depth molecular response prior to conception appeared to correlate well with restoration of disease control on TKI recommencement though duration of MMR did not appear to be as important. While interruption of TKI treatment for pregnancy usually leads to loss of molecular response, loss of hematological response is uncommon and disease control is reestablished with resumption of therapy in the majority of women. Refereed/Peer-reviewed |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |